1. Home
  2. QH vs PMCB Comparison

QH vs PMCB Comparison

Compare QH & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

HOLD

Current Price

$1.29

Market Cap

6.6M

ML Signal

HOLD

Logo PharmaCyte  Biotech Inc.

PMCB

PharmaCyte Biotech Inc.

HOLD

Current Price

$0.96

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QH
PMCB
Founded
2012
1996
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.6M
5.3M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
QH
PMCB
Price
$1.29
$0.96
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
792.0K
9.9M
Earning Date
09-26-2025
12-15-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.33
0.01
Revenue
$357,118,848.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.84
$162.06
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.63
52 Week High
$169.07
$1.90

Technical Indicators

Market Signals
Indicator
QH
PMCB
Relative Strength Index (RSI) 44.82 52.21
Support Level $1.09 $0.94
Resistance Level $2.20 $1.51
Average True Range (ATR) 0.22 0.20
MACD 0.20 0.02
Stochastic Oscillator 34.45 35.97

Price Performance

Historical Comparison
QH
PMCB

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services.

About PMCB PharmaCyte Biotech Inc.

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Share on Social Networks: